IP Library › Granted Patent US 9,273,142
Granted Patent B2
US 9,273,142 · App. 14/050,773 · Granted Mar 1, 2016

Glycan-interacting compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,273,142
App. No.
14/050,773
Granted
Mar 1, 2016
Kind
B2
Abstract

The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.

Claims (3)

1. An antibody comprising a heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 2.

2. A humanized antibody comprising a VH comprising the complimentarity determining regions (CDRs) of the VH domain of SEQ ID NO: 1 and a VL comprising the CDRs of the VL domain of SEQ ID NO: 2.

3. A composition comprising the antibody of claim 1 or 2 and an excipient.

Assignments (4)
CHANGE OF NAME Recorded Feb 22, 2021
From: SEATTLE GENETICS, INC.
To: SEAGEN INC.
Reel/Frame 055362/0182 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2019
From: SIAMAB THERAPEUTICS, INC.
To: SEATTLE GENETICS, INC.
Reel/Frame 050414/0643 →
CHANGE OF NAME Recorded Jul 8, 2014
From: SIALIX, INC.
To: SIAMAB THERAPEUTICS, INC.
Reel/Frame 033281/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2013
From: GHADERI, DARIUS; DA SILVA, ANA PAULA GALVAO; BEHRENS, JEFFREY; HERMANN, JULIE; HURTADO-ZIOLA, NANCY
To: SIALIX INC.
Reel/Frame 031627/0126 →